CIK细胞治疗恶性实体瘤的临床疗效评价  

Evaluation of the Clinical Efficacy of CIK Cell for Malignant Solid Tumors

作　　者：罗利琼[1] 王继红[1] 霍丹[1] 张小丽[1] 张高[1] 胡林[1] 马玉芳[1] 

机构地区：[1]武汉科技大学附属天佑医院肿瘤科,湖北武汉430064

出　　处：《中国医药指南》2013年第8期34-36,共3页Guide of China Medicine

摘　　要：目的评价CIK细胞治疗恶性实体瘤的临床疗效及安全性。方法选择恶性实体瘤患者48例,分为单纯化疗组、CIK细胞联合化疗治疗组、CIK细胞治疗组。采用卡氏评分(Karnofsky)评价生活质量及体力改善状况;通过比较客观有效率和疾病控制率评价近期疗效;从治疗开始至患者死亡或最后/次随访时间止,观察并记录患者的生存时间;评价CIK细胞治疗安全性。结果 CIK治疗组患者治疗后一般情况有所改善,特别是在改善食欲和睡眠,增加体质量和体力方面。这可能是CIK细胞治疗的优势所在。但是三组患者在客观有效率方面和疾病控制率方面,单纯化疗组和CIK细胞联合化疗治疗组,与CIK治疗组有显著性差异(P<0.05)。在生存时间方面CIK治疗组患者的生存时间低于单纯化疗组和CIK细胞联合化疗治疗组(P<0.05)。在整个临床观察期间,除有2例患者出现低热症状外,未出现其他不良反应。结论 CIK细胞免疫治疗能改善患者的一般状况,安全性好,是恶性实体瘤的患者在进行化疗治疗之余的有效辅助治疗手段。Objective To evaluate the clinical efficacy and secruity of CIK cell for malignant solid tumors. Methods 48 patients who suffered from malignant solid tumors, were divide into the chemotherapy alone group, CIK cells combined with chemotherapy treatment group and CIK treatment group. Evaluation of the quality of life and physical strength to improve the situation with karnofsky score; to compare overall response rate and disease control rate among the three groups; death from the start of treatment to patients or follow-up time for the last / time to observe and record the patient＇s survival time; security evaluation CIK cell therapy. Results CIK treatment group particularly improved appetite and sleep, increased body weight and physical aspects. This may be the advantage of the CIK cell therapy. But the three groups of patients in overall response rate and disease control rate, the chemotherapy alone group and CIK cells combined with chemotherapy treatment group, a significant difference （P〈0.05） with CIK treatment group. CIK treatment group patients survival time is less than the chemotherapy alone group and CIK cells combined with chemotherapy treatment group （P〈0.05）. Throughout the clinical observation period, except for two cases of patients with low-grade fever symptoms, not the other adverse reactions. Conclusion CIK cell immunotherapy can improve the patient＇s general condition, security is an effective means of adjuvant therapy in patients with malignant solid tumors during chemotherapy treatment.

关 键 词：细胞因子诱导的杀伤细胞 过继免疫疗法 恶性实体瘤 

分 类 号：R730.58[医药卫生—肿瘤]